IPO - Annovis Bio, Inc.
Form Type: 8-K
Filing Date: 2025-02-05
Corporate Action: Ipo
Type: New
Accession Number: 000110465925009279
Filing Summary: On February 3, 2025, Annovis Bio, Inc. entered into an Underwriting Agreement with ThinkEquity LLC for an underwritten public offering of 5,250,000 units. Each unit consists of one share of common stock and one warrant to purchase an additional share. The offering price per unit is $4.00, aiming for gross proceeds of $21,000,000. The associated Warrants have an exercise price of $5.00 and are immediately exercisable for five years. The Company plans to utilize the net proceeds from this offering to advance the clinical development of its lead compound, Buntanetap, in a Phase 3 study for Alzheimer’s disease, along with funding for working capital and general corporate purposes. The securities are issued under the Company’s effective shelf Registration Statement on Form S-3.
Document Link: View Document
Additional details:
Date Of Report: 2025-02-03
Underwriting Agreement Date: 2025-02-03
Units Offered: 5,250,000
Price Per Unit: $4.00
Gross Proceeds: $21,000,000
Exercise Price Warrant: $5.00
Warrant Expiration: five years from the date of issuance
Use Of Proceeds: clinical development of Buntanetap, working capital and general corporate purposes
Comments
No comments yet. Be the first to comment!